Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Seeking investors

Biotec Pharmacon

Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The company focuses on new and effective solutions within wound care, cancer therapies and other immune related disease areas, and aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.

Read more

Xvivo

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation.

Read more

Chundsell Medicals

Annual & quarterly reports
More reports

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Read more
More investment opportunities

Partnership opportunities

No items found.
More partnership opportunities

Investors

No items found.

Mass Medical Angels

Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired.

Read more

HealthCap

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.

Read more
More investors